Trade-Ideas LLC identified




) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified Cryolife as such a stock due to the following factors:

  • CRY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $5.1 million.
  • CRY has traded 28.17909999999999826059138285927474498748779296875 options contracts today.
  • CRY is making at least a new 3-day high.
  • CRY has a PE ratio of 44.
  • CRY is mentioned 1.90 times per day on StockTwits.
  • CRY has not yet been mentioned on StockTwits today.
  • CRY is currently in the upper 20% of its 1-year range.
  • CRY is in the upper 35% of its 20-day range.
  • CRY is in the upper 45% of its 5-day range.
  • CRY is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CRY with the Ticky from Trade-Ideas. See the FREE profile for CRY NOW at Trade-Ideas

More details on CRY:

CryoLife, Inc., together with its subsidiaries, manufactures and distributes medical devices worldwide. It also processes and distributes implantable human tissues for use in cardiac and vascular surgeries. The company operates in two segments, Medical Devices and Preservation Services. The stock currently has a dividend yield of 0.8%. CRY has a PE ratio of 44. Currently there are 3 analysts that rate Cryolife a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Cryolife has been 192,300 shares per day over the past 30 days. Cryolife has a market cap of $458.2 million and is part of the health care sector and health services industry. The stock has a beta of 1.02 and a short float of 2.8% with 3.04 days to cover. Shares are up 32.6% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.


TheStreet Quant Ratings

rates Cryolife as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 6.3%. Since the same quarter one year prior, revenues rose by 32.5%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 567.5% when compared to the same quarter one year prior, rising from -$0.50 million to $2.35 million.
  • The gross profit margin for CRYOLIFE INC is rather high; currently it is at 66.27%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, CRY's net profit margin of 4.98% significantly trails the industry average.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.